Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senators Push Back On Global Digital Taxes, While US Pulls Out Of OECD Technology Tax Talks

Executive Summary

Two US senators said last week that Organization for Economic Cooperation and Development (OECD) member countries should drop plans to impose digital taxes on US businesses – a scheme that would impact firms that make digital health devices, including Apple, Siemens, Johnson & Johnson and IBM.

You may also be interested in...



US Retaliatory Tariffs On France Supported By Senators After French Impose Digital Services Tax

France’s move to impose digital services taxes has spurred the US Trade Representative to impose retaliatory tariffs on French goods, an action supported by two US senators.

FDA Explains Why It Approved Apple Watch's De Novo Despite Missing Primary Endpoint

De novo summary documents published by the US FDA sheds more light on the agency’s work approving two de novos for Apple Watches last year. At the time, the approvals sparked concern from industry stakeholders on whether the company received preferential treatment. Former FDA Commissioner Scott Gottlieb pushed back against the notion in a lengthy blog post late last year.

FDA's Speedy Apple Watch De Novos Raise Questions For Industry

The recent US FDA de novo approvals for heart-rhythm analysis software on Apple's latest Apple Watch, which took about 30 days from submission to a decision that aligned with Apple's high-profile launch event, raised eyebrows in the medtech industry. Some in industry are concerned that the tech giant received preferential treatment over smaller companies, setting a bad precedent. But some say it could be a positive sign for the digital health industry at large.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel